Evaluation of <Superscript>99m</Superscript>TcN–moxifloxacin dithiocarbamate,as a potential radiopharmaceutical for scintigraphic localization of infectious foci

^99mTc ≡ N-Pazufloxacin dithiocarbamate (^99mTc ≡ N-PZN) complex was synthesized through the [^99mTc ≡ N]²⁺ core and its aptness was radiochemically and biologically evaluated in terms of radiochemical purity (RCP) in saline, in vitro stability in serum, in vitro bacterial uptake and percent in vivo uptake in male Wister rats (MWR) artificially infected with alive and heat killed Escherichia coli (E. coli). The ^99mTc ≡ N-PZN complex showed more than 90% RCP up to 4 h after reconstitution in normal saline at room temperature with a maximum RCP value of 98.40 ± 0.28% (at 30 min). At 37 °C in serum the complex showed stable behaviour up to 4 h with the appearance of 15.95% undesirable by products within 16 h of the incubation. The complex showed saturated in vitro binding with E. coli with a maximum uptake of 74.25 ± 0.50% (at 90 min). Normal biodistribution behaviour was noted with a sixfold higher accumulation in the muscle of the MWR, artificially infected with live E. coli as compared to the MWR infected with heat killed E. coli, inflamed and normal muscle. The high RCP in saline, elevated in vitro stability in serum, saturated in vitro binding with E. coli and the sixfold higher accumulation in the infected (live) muscle of the MWR as compared to the inflamed and normal muscle, recognized the aptness of the ^99mTc ≡ N-PZND complex as a prospective E. coli in vivo infection radiotracer.     

Radiosynthesis and biological evaluation of <Superscript>99m</Superscript>TcN-sitafloxacin dithiocarbamate as a potential radiotracer for <Emphasis Type="Italic">Staphylococcus aureus</Emphasis> infection

Sitafloxacin dithocarbamate (SFDE) was synthesized, radiolabeled with technetium-99m (^99mTc) using [^99mTc-N]²⁺ core and evaluated its biological efficacy as a potential radiotracer for Staphylococcus aureus (S. aureus) infection in artificially infected rats (AIRT) and rabbits (AIRB). The radiochemical stability of the ^99mTc labeled SFDE (^99mTcN-SFDE) in saline and serum was determined by radio-HPLC and TLC methods, respectively. After, 1 min of reconstitution the value of radiochemical purity (RCP) was 99.00 ± 0.20% and was remained more than 90% unwavering even after 240 min of the radiolabeling. The ^99mTcN-SFDE complex showed similar radiochemical permanence behavior in serum at 37 °C. The complex showed almost six fold higher specific in vitro binding with living than heat killed S. aureus. Biodistribution behavior was evaluated in S. aureus AIRT and whole body imaging (WBI) in AIRB, respectively. Seven fold up take was observed in infected muscle of the AIRT as compared to inflamed and normal muscles. The disappearance of activity from blood and appearance in urinary system indicated normal route of excretion of the complex. Scintigraphically, it was confirmed that the labeled SFDE was higher accumulated in the infected muscle higher than in inflamed and normal muscle. The high radiochemical stability in saline and serum, specific in vitro binding with S. aureus, precise in vivo distribution in S. aureus AIRT and targeted WBI in AIRB confirmed the possibility of the ^99mTcN-SFDE complex as a potential and promising S. aureus infection radiotracer.     

<Superscript>99m</Superscript>TcN–gatifloxacin dithiocarbamate complex: a novel multi-drug-resistance <Emphasis Type="Italic">Streptococcus pneumoniae</Emphasis> (MRSP) infection radiotracer

Gatifloxacin (GTN) was derivatized to its dithiocarbamate derivative and its radiolabeling with technetium-99m (^99mTc) using the [^99mTc≡N]²⁺ core was investigated. The appropriateness of the ^99mTcN–gatifloxacin dithiocarbamate (^99mTcN–GTND) complex as a potential multi-drug-resistance Streptococcus pneumoniae (MRSP) infection radiotracer was evaluated in terms of stability in saline, serum, in vitro binding with MRSP and biodistribution in artificially MRSP infected Male Wistar Rats (MWR). In saline the ^99mTcN–GTND complex showed more than 90% labeling yield up to 4 h with a maximum yield of 98.25 ± 0.20%, after reconstitution. In serum the ^99mTcN–GTND complex showed stability up to 16 h of incubation with the appearance of insignificant 15.95% undesirable side products. The ^99mTcN–GTND complex demonstrated saturated in vitro binding with MRSP with a maximum value of 75.50 ± 1.00% (at 90 min). In MWR model of group A, almost six times higher uptake of the labeled GTND was monitored in the muscle of MWR infected with live MRSP as compared to the inflamed and normal muscles. Based on the higher labeling yield in saline, in vitro stability in serum, saturated in vitro binding with live MRSP and promising biodistribution in MWR model we recommend ^99mTcN–gatifloxacin dithiocarbamate complex as a potential MRSP infection radiotracer.     

Simulation of chlorination reaction behavior of hull wastes by using the HSC code

Nitrofurantoin (NFN) radiolabeling with technetium-99m (^99mTc) was investigated using different concentration of the NFN, sodium pertechnetate (Na^99mTcO₄), reducing agent (SnCl₂) at different pH ranges (5.1–6.00). The suitability of the ^99mTc-NFN was evaluated in terms of the radiochemical purity (RCP) yield, in vitro stability in saline, serum, in vitro binding with E. coli, biodistribution in E. coli infected model rat (ERT), and scintigraphic accuracy in E. coli infected model rabbit (EBT). The superlative radiochemical succumb at 2.5 mg NFN, 125 μL of SnCl₂ (1 μg/μL in 0.01 N HCl), 2.5 mCi of Na^99mTcO₄, at pH 5.2 at 30, 60, 90, and 120 min after reconstitution was 64.50 ± 0.11, 97.50 ± 0.16, 94.25 ± 0.10, 92.15 ± 0.14 and 90.75 ± 0.0.13%. The complex was found stable in saline and serum for 90% up to 120 min and showed 50–65% in vitro binding with E. coli. The absorption of the ^99mTc-NFN, primarily at E. Coli infected (ECT) muscle of ERT was lower but after 60 min it went up to 7.25 ± 0.17%. The absorption in the blood, liver, spleen, stomach, intestines, inflamed muscle (N.T1) and normal muscle (N.T2) went down while in the kidney and urine it went up with time. The ratio of the ECT/N.T1 was 7:1 and N.T2/N.T1 was 2:1. The Whole Body Static (WBS) imaging of the ERB confirmed the suitability of the ^99mTc-NFN as radiotracer. The superlative radiochemical succumb, significant in vitro stability in saline and serum, in vitro binding with E. coli, ideal biodistribution and scintigraphic accuracy confirmed the viability of the ^99mTc-NFN as radiotracer for infection.     

Synthesis,radiochemical and biological characteristics of <Superscript>99m</Superscript>Tc-8-hydroxy-7-substituted quinoline complex: a novel agent for infection imaging

2,2′-[(8-hydroxyquinolin-7-yl)methylazanediyl]diacetic acid (HQMADA) was synthesized via reaction of 8-hydroxyquinoline with iminodiacetic acid in presence of paraformaldehyde with a yield of 27%. The obtained compound was well characterized via different analytical techniques. Labeling of the synthesized compound with technetium-99m in pertechnetate form (^99mTcO₄ ⁻) in the presence of stannous chloride dihydrate was carried out via chelation reaction. The reaction parameters that affect the labeling yield such as HQMADA concentration, stannous chloride dihydrate concentration, pH of the reaction mixture, and reaction time were studied to optimize the labeling conditions. Maximum radiochemical yield of ^99mTc-HQMADA complex (91.9%) was obtained by using 1.5 mg HQMADA, 50 μg SnCl₂·2H₂O, pH 8 and 30 min reaction time. Biodistribution studies in mice were carried out in experimentally induced infection in the left thigh using E. coli. ^99mTc-HQMADA complex showed higher uptake (T/NT = 5.5 ± 0.3) in the infectious lesion than the commercially available ^99mTc-ciprofloxacin (T/NT = 3.8 ± 0.8). Biodistribution studies for ^99mTc-HQMADA complex in Albino mice bearing septic and aseptic inflammation models showed that ^99mTc-HQMADA complex able to differentiate between septic and aseptic inflammation.     

Synthesis of techentium-99m labeled clinafloxacin (99mTc�CCNN) complex and biological evaluation as a potential Staphylococcus aureus infection imaging agent

In the present study synthesis of the ^99mTc?CCNN complex and its efficacy as a prospective Staphylococcus aureus (S. aureus) infection imaging agent was assessed. The ^99mTc?CCNN complex was characterized in terms of stability in saline, serum, in vitro binding with S. aureus and in vivo percent absorption in male Wister rats (MWR) infected with live and heat killed S. aureus. Radiochemically the ^99mTc?CCNN complex showed stable behavior in saline and serum at different intervals. At 30 min after reconstitution the complex showed maximum radiochemical purity (RCP) yield of 97.55 ± 0.22%. The RCP yield decreased to 90.50 ± 0.18% within 240 min. In serum, 18.15% unwanted side product was appeared within 16 h of the incubation. In vitro saturated binding with S. aureus was observed at different intervals with a 62.00% maximum at 90 min. Normal percent in vivo uptake was observed in MWR artificially infected with live S. aureus with a five times higher in the infected muscle as compared to the inflamed and normal muscles. No difference in the percent uptake of the complex in MWR infected with heat killed S. aureus in the infected, inflamed and normal muscles were observed. Based on the promising in vitro and in vivo radiochemical and biological characteristics, we recommend the ^99mTc?CCNN complex for in vivo localization of the S. aureus infectious foci.     

Synthesis,radiolabelling and biodistribution of HYNIC-Tyr<Superscript>3</Superscript> octreotide: a somatostatin receptor positive tumour imaging agent

In vivo imaging of tumours using radiolabelled somatostatin (SST) analogues has become an accepted clinical tool in oncology. HYNIC-Tyr³ octreotide and Tyr³ octreotide were synthesized by FMOC solid-phase peptide synthesis using a semi-automated synthesizer. These were analyzed and purified by RP-HPLC, mass spectroscopy, IR spectroscopy, ¹H NMR and ¹³C NMR. The prochelator 6-BOC-HYNIC was also synthesised and characterised indigenously. HYNIC-Tyr³ octreotide was labelled with ^99mTc using Tricine and EDDA as coligand by SnCl₂ method. Labelling with ^99mTc was performed at 100 °C for 15 min and radiochemical analysis by ITLC and HPLC methods. The radiochemical purity of the complex was over 98% and log p value was found to be −1.27 ± 0.12. The stability of radiolabelled peptide complex was checked at 37 °C up to 24 h. Blood clearance and protein-binding study was also performed. In vivo biodistribution studies in rat showed uptake of ^99mTc-HYNIC-TOC in kidney than any other organs. The blood clearance was faster with rapid excretion through kidneys and relatively low uptake in liver.     

Synthesis of the <Superscript>99m</Superscript>Tc(CO)<Subscript>3</Subscript>–trovafloxacin dithiocarbamate complex and biological characterization in artificially methicillin-resistant <Emphasis Type="Italic">Staphylococcus aureus</Emphasis> infected rats model

The radiolabeling of trovafloxacin dithiocarbamate (TVND) with technetium-99m using [^99mTc-N]²⁺ core was investigated and biologically assessed as prospective infection imaging agent. The achievability of the ^99mTcN-TVND complex as a future MRSA infection radiotracer was investigated in artificially methicillin-resistant Staphylococcus aureus (MRSA) infected male Sprague–Dawley rats (MSDR). Radiochemically the ^99mTcN-TVND complex was characterized in terms of radiochemical purity (RCP) in saline, in vitro permanence in serum, in vitro binding with MRSA and biodistribution in living and heat killed MRSA infected MSDR. Radiochemically the complex showed stability in saline with a 97.90 ± 0.22% yield and serum at 37 °C up to 4 h. The ^99mTcN-TVND complex showed saturated in vitro binding with MRSA. Normal in vivo uptake in the MRSA infected MDRS was observed with a five fold uptake in the infected muscle as compared to inflamed and normal muscles. The high RCP values, in vitro permanence in serum, better in vitro binding with MRSA, biodistribution behavior and the target to non-target (infected to inflamed muscle) ratios posed the ^99mTcN-TVND complex as a promising MRSA infection radiotracer.     

Preparation and preliminary evaluation of <Superscript>211</Superscript>At-labeled amidobisphophonates

In this paper, 3-amino-1-hydroxypropylidene-1,1-bisphosphonate(APB), a amidobisphophonate was synthesized and labeled with the α-emitter ²¹¹At by an indirect method using N-succinimidyl 5-(tributylstannyl)-3-pyridinecarboxylate (SPC) as a bi-functional linker, and the conjugated amidobisphophonate (²¹¹At-SAPC-APB) was preliminarily evaluated in vitro and in vivo by comparison with free astatide (²¹¹At⁻) and ^99mTc-MDP. 3-amino-1-hydroxypropylidene-1,1-bisphosphonate(APB) was prepared using β-alanine as the starting material. With SPC bi-functional linker, APB was conjugated with ²¹¹At in a labeling yield of 80–90% with radiochemical purity of more than 99%. The conjugated amidobisphophonate (²¹¹At-SAPC-APB) exhibited considerable stability in vitro, in that the radiochemical purity of ²¹¹At-SAPC-APB was still more than 98% in 0.1 mol/L PBS (pH 7.6) or in fetal calf serum, even stayed for 24 h at room temperature (RT). Biodistribution of ²¹¹At-SAPC-APB was investigated in NIH strain mice by I.V injection. The results showed that ²¹¹At-SAPC-APB could rapidly locate in shank, with the maximum uptake of 23.70 ± 2.29% I.D/g at 6 h, earlier than that of ^99mTc-MDP at 12 h, and stayed in the bone for long time. Moreover, ²¹¹At-SAPC-APB uptake in some key organs or tissues, especially in thyriod, stomach, lung and spleen, was much less than that of free astatide (²¹¹At⁻), implying that ²¹¹At-SAPC-APB was constantly stable in vivo as well as in vitro. These results indicated that ²¹¹At-SAPC-APB will be a suitable candidate for the targeted radiotherapy of bone metastases and should be further investigated.     

Radiocharacterization of the 99mTc�Crufloxacin complex and biological evaluation in Staphylococcus aureus infected rat model

^99mTc?Crufloxacin (^99mTc?CRUN) complex was prepared by reaction of different amounts of reduced sodium pertechnetate with different amount of Rufloxacin (RUN) antibiotic for the in vivo scintigraphic localization of the Staphylococcus aureus (S. aureus) infectious foci in Male Wister Rats (MWR) model. The ^99mTc?CRUN complex was radiochemically and biologically characterized in terms of radiochemical stability in saline, serum, in vitro binding with S. aureus and biodistribution in artificially infected with S. aureus MWR. The ^99mTc?CRUN complex showed stability more than 90% up to 240 min in normal saline with a maximum stability value of 98.10 ± 0.18% at 30 min after reconstitution. At 37 °C the complex showed in vitro permanence in serum up to 16 h with 13.90% side products during incubation. The ^99mTc?CRUN complex showed saturated in vitro binding with S. aureus at different intervals with a maximum uptake value of 71.50%. Infected to normal muscle, infected to inflamed and inflamed to normal muscles ratios were approximately 6.04, 4.31 and 1.40. Based on the stability of the complex in saline, serum, in vitro binding with S. aureus and biodistribution results, the ^99mTc?CRUN complex is recommended for in vivo scintigraphic localization of the S. aureus in vivo infectious foci in human.     

Radiosynthesis and Biodistribution of <Superscript>99m</Superscript>Tc-Metronidazole as an <Emphasis Type="Italic">Escherichia coli</Emphasis> Infection Imaging Radiopharmaceutical

Bacterial infection poses life-threatening challenge to humanity and stimulates to the researchers for developing better diagnostic and therapeutic agents complying with existing theranostic techniques. Nuclear medicine technique helps to visualize hard-to-diagnose deep-seated bacterial infections using radionuclide-labeled tracer agents. Metronidazole is an antiprotozoal antibiotic that serves as a preeminent anaerobic chemotherapeutic agent. The aim of this study was to develop technetium-99m-labeled metronidazole radiotracer for the detection of deep-seated bacterial infections. Radiosynthesis of ^99mTc-metronidazole was carried by reacting reduced technetium-99m and metronidazole at neutral pH for 30 min. The stannous chloride dihydrate was used as the reducing agent. At optimum radiolabeling conditions, ~ 94% radiochemical was obtained. Quality control analysis was carried out with a chromatographic paper and instant thin-layer chromatographic analysis. The biodistribution study of radiochemical was performed using Escherichia coli bacterial infection-induced rat model. The scintigraphic study was performed using E. coli bacterial infection-induced rabbit model. The results showed promising accumulation at the site of infection and its rapid clearance from the body. The tracer showed target-to-non-target ratio 5.57 ± 0.04 at 1 h post-injection. The results showed that ^99mTc-MNZ has promising potential to accumulate at E. coli bacterial infection that can be used for E. coli infection imaging.     

Synthesis,biological evaluation and biodistribution of the <Superscript>99m</Superscript>Tc–Garenoxacin complex in artificially infected rats

The labeling of garenoxacin (GXN) with technetium-99m (^99mTc) using different concentrations of GXN, sodium pertechnetate (Na^99mTcO₄), stannous chloride dihydrate (SnCl₂·2H₂O) at different pH was investigated and evaluated in terms of in-vitro stability in saline, serum, binding with multi-resistant Staphylococcus aureus (MDRSA) and penicillin-resistant Streptococci (PRSC) and its biodistribution in artificially MDRSA and PRSC infected rats. ^99mTc–GXN complex with 97.45 ± 0.18% radiochemical stability was prepared by mixing 3 mg of GXN with 3 mCi of Na^99mTcO₄ in the presence of 150 μL of SnCl₂·2H₂O (1 μg/μL in 0.01 N HCl) at a pH 5.6. The radiochemical stability of the complex was evaluated in normal saline up to 240 min of reconstitution. It was observed that the complex showed maximum RCP values after 30 min of the reconstitution and remained more than 90% up to 240 min. The complex showed radiochemical stability in normal saline at 37 °C up to 16 h with a 17.80% de-tagging. The complex showed saturated in-vitro binding with living MDRSA and PRSC as compared to the insignificant binding with heat killed MDRSA and PRSC. Biodistribution behavior of the complex was assessed in artificially infected with living and heat killed MDRSA and PRSC rats. It was observed that the accumulation of the complex in the infected (live MDRSA and PRSC) tissue of the rats was almost five fold than in the inflamed and normal tissue. The high radiochemical stability in normal saline at room temperature, promising in-vitro stability in serum at 37 °C, saturated in-vitro binding with living MDRSA and PRSC, specific biodistribution behavior and high infected (target) to normal (non-target) tissue and low inflamed (non-target) to normal (non-target) tissue ratios we recommend ^99mTc–GXN complex for in-vivo localization of infection caused by MDRSA and PRSC effective stains.     

Synthesis and biodistribution of a novel <Superscript>99m</Superscript>Tc-DMSA-metronidazole ester as a potential tumor hypoxia imaging agent

The dimercaptosuccinic acid metronidazole ester (DMSAMe) was synthesized and radiolabeled with ^99mTc to form the ^99mTc-DMSAMe complex in high yield. The radiochemical purity of the ^99mTc-DMSAMe complex was over 90%, as measured by TLC and by HPLC, without any notable decomposition at room temperature over a period of 6 h. Its partition coefficient indicated that it was a lipophilic complex. The tumor cell experiment and the biodistribution in mice bearing S 180 tumor showed that the ^99mTc-DMSAMe complex had a certain hypoxic selectivity and accumulated in the tumor with high uptake and good retention. The tumor/blood and tumor/muscle ratios increased with time, suggesting it would be a possible tumor hypoxia imaging agent.     

Formulation of a freeze-dried kit for the preparation of <Superscript>99m</Superscript>Tc-tetrofosmin

A new formulation of a freeze-dried kit for the labeling of tetrofosmin with technetium-99m has been developed. The kit contains lyophilized mixture of 0.320 mg tetrofosmin [6,9-bis(2-ethoxyethyl)-3,12-dioxa-6,9-diphosphatetradecane], 0.025 mg stannous chloride dihydrate, 5 mg sodium tartrate and 5 mg sodium hydrogen carbonate. The product contains no antimicrobial preservative. When ^99mTc pertechnetate up to 6 mL saline containing 200 mCi is added to lyophilized mixture, a lipophilic, cationic ^99mTc complex is formed, ^99mTc-tetrofosmin. The performance of newly developed kit is compared with commercially available MYOVIEW kit for heart imaging. The patient studies show that the images of heart obtained by ^99mTc-tetrofosmin prepared by new formulation are equally good to MYOVIEW.     

A novel electrochemical <Superscript>99</Superscript>Mo/<Superscript>99m</Superscript>Tc generator

A novel electrochemical process to avail clinical grade ^99mTc from (n,γ)⁹⁹Mo has been demonstrated. The electrochemical parameters were optimized to maximize the ^99mTc yield with minimal ⁹⁹Mo contamination. ⁹⁹Mo/^99mTc generators containing up to 29.6 GBq (800 mCi) ⁹⁹Mo were developed and their performance were extensively evaluated for 10 days without changing the operating conditions. Very high radioactive concentration of ^99mTcO₄ ⁻ of acceptable quality, commensurate with hospital radiopharmacy requirements could be availed from the system with >90% yield. The compatibility of the product for the formulation of ^99mTc labeled radiopharmaceuticals such as ^99mTc-DMSA and ^99mTc-EC was found to be satisfactory in terms of high labeling yields. The proposed route represents an important step for enhancing the scope of accessing clinical grade ^99mTc from low specific activity (n, γ)⁹⁹Mo.     

Synthesis and biological evaluation of <Superscript>99m</Superscript>Tc-DHPM complex: a potential new radiopharmaceutical for lung imaging studies

In the recent years interests on dihydropyrimidinone and their analogues have increased potentially due to their wide range of pharmacological/biological activities. Synthesis, radiolabeling with technetium-99 m (^99mTc) and biological evaluation of 5-etoxycarbonyl-4-phenyl-6-methyl-3,4-dihydro-(1H)-pyrimidine-2-one (DHPM) were studied in this present work. After synthesis complexation of DHPM with ^99mTc was carried out using stannous chloride as the reducing agent. The complex (^99mTc-DHPM) was characterized by thin layer chromatography, radio-HPLC technique and determination of partition co-efficient. Radiochemical stability and particle size distribution of the complex were also measured. Biodistribution/scintigraphy studies were performed in rats and rabbits to evaluate the pharmacological characteristics of this complex. The radiochemical purity of the complex was over 95% as studied by thin layer chromatography and radio-HPLC. It was stable over 24 h at room temperature. Its partition coefficient indicated that it was a lipophilic complex. According to the European Pharmacopeia, >80% of ^99mTc labeled radiopharmaceutical (^99mTc-MAA) in the size range 10–50 μm, must be accumulated in the lungs 15 min after intravenous administration. In this study >85% of the ^99mTc-DHPM complex in the average size of 40 μm. Biodistribution studies of ^99mTc-DHPM in rat revealed that the complex accumulated in the lung with high uptake and good retention after intravenous administration. Scintigraphic studies in rabbit also revealed that most of the administered radiolabeled complex was accumulated in the lungs and after 1 h slowly excreted through the renal system. The lung uptake (ID%/g) was 10.12, 9.67, 8.60 and 5.01 and the lung/liver ratio was 7.49, 2.88, 2.62 and 1.87 at 2, 15, 30 and 60 min post-injection, respectively. These results suggested that ^99mTc-DHPM could be suitable as a potential lung perfusion imaging agent. Further studies with ^99mTc-DHPM and its derivatives are warranted to develop new ^99mTc-labeled imaging agents for clinical applications.     

Preparation of <Superscript>99m</Superscript>Tc-PQQ and preliminary biological evaluation for the NMDA receptor

Pyrroloquinoline quinone (PQQ), an essential nutrient, antioxidant, redox modulator and nerve growth factor found in a class of enzymes called quinoproteins, was labeled with ^99mTc by using stannous fluoride (SnF₂) method. Radiolabeling qualification, quality control and characterization of ^99mTc-PQQ and its biodistribution studies in mice were performed and discussed. Effects of pH values, temperature, time and reducing agents concentration on the radiolabeling yield were investigated. The quality control procedure of ^99mTc-PQQ was determined by thin layer chromatography (TLC), radio high-performance liquid chromatography (RHPLC) and paper electrophoresis methods. The average radiolabeling yield was 94 ± 1% under optimum conditions of 0.99 mg of PQQ, 30 μg of SnF₂, 0.5 mg of ethylenediaminetetraacetic acid disodium salt (EDTA-2Na) and 18.5 MBq of Na^99mTcO₄ at pH 6 and 25 °C with a response volume of 1 ± 0.1 mL. ^99mTc-PQQ was stable and anionic. Lipid–water partition coefficient of ^99mTc-PQQ was −1.49 ± 0.16. The pharmacokinetics parameters of ^99mTc-PQQ were t _1/2α = 18.16 min, t _1/2β = 100.45 min, K ₁₂ = 0.013 min⁻¹, K ₂₁ = 0.017 min⁻¹, K _e = 0.016 min⁻¹, AUC (area under the curve) = 1040.78 ID% g⁻¹ min and CL (plasma clearance) = 0.096 mL min⁻¹. The dual-exponential equation was Y = 10.88e^−0.038t  + 5.21e^−0.0069t . The biodistribution of ^99mTc-PQQ was studied in ICR (Institute for Cancer Research 7701 Burhelme Are., Fox Chase, Philadelphia, PA 1911 USA) mice. In vitro autoradiographic studies clearly showed that the ^99mTc-PQQ radioactivity accumulated predominantly in the hippocampus and cortex, which had a high density of N-methyl-d-aspartate Receptor (NMDAR). The enrichment can be blocked by NMDAR redox modulatory site antagonists-ebselen (EB) and ^99mTc-PQQ is therefore a promising candidate for the molecular imaging of NMDAR. To date, however, there have been no studies characterizing ^99mTc-PQQ.     

The interaction of <Superscript>99m</Superscript>Tc with pyrimidine compounds

The reaction of ^99mTc of different oxidation states (+7, +4) with 2-thiouracil and 5-nitrobarbituric acid have been studied at different temperatures, pH and concentrations. The reaction mixtures have been analyzed at different times using thin layer chromatography (TLC) and a radio detector to show the peaks at the plates. ^99mTc is obtained from the Mo generators with oxidation state (+7). The use of SnCl₂ as a reducing agent gave ^99mTc with oxidation state (+4). It is very difficult to separate the complexes formed from the reactions in very small concentration. The percentage of ^99mTc and its oxidation state involved in the complexes can be determined. The labeling efficiencies (percentage of complex) in the reaction of ^99mTc⁺⁷ with 5-nitro-barbituric-acid increases mostly at pH  10. Both oxidation states of ^99mTc(+7, +4) can be detected at pH’s 4 and 10, but at pH  4, the reduced form ^99mTCO₂, is more pronounced. At pH  7 no complexes were detected and most of ^99mTc remains as ^99mTCO₄ ⁻ . By increasing the ligand concentration, the labeling efficiencies of the complex increases. For the reaction of ^99mTc of oxidation states (+4, +7) with 2-thiouracil at different temperatures and analytical times it is concluded that several complexes with different R_f values were observed in equilibrium and most of these complexes were unstable.     

<Superscript>99m</Superscript>Tc-roxifiban: a potential molecular imaging agent for the detection and localization of acute venous thrombosis

^99mTc-roxifiban was obtained in a high radiochemical yield (98.4%) by complexing ~750 MBq ^99mTc with 2.5 mg roxifiban in the presence of 150 µg SnCl₂·2H₂O. Factors affecting the labelling yield were investigated and optimized. The complex was lipophilic and stable in saline and serum for more than 8 h. The complex structure prediction and molecular docking to its target activated GPIIb/IIIa receptor were performed. The tracer in vitro binding to activated platelets was high (27–32%). In vivo evaluation was performed through clearance, biodistribution and imaging studies in rats. All results supported the usefulness of the tracer as thrombus imaging agent.     

Preparation of <Superscript>99m</Superscript>Tc-metronidazole as a model for tumor imaging

Metronidazole (MTNZ) is an antiprotozoa drug, could be labeled with the ^99mTc. MTZL could be used as an ideal vehicle to deliver radioactive decay energy of ^99mTc to the sites of tumor, thus facilitate tumor imaging. The process of labeling was done using tin chloride as reducing agent. The optimum conditions required to label 25 μg MTZL were 100 μg stannous chloride, 30 min reaction time, room temperature at pH 7–9 using 0.5 M phosphate buffer. The radiochemical purity of the labeled compound, at the above conditions, was determined using paper chromatography. The yield was about 93%. About 2.5 × l0⁶ of Ehrlich Ascites Carcinoma (EAC) was injected intrapritoneally (i.p) to produce ascites and intramuscularly (i.m) in the right thigh to produce solid tumor in female mice. Biodistribution studies were carried out by injecting solution of ^99mTc-MTZL in normal and tumor bearing mice. The uptake in ascites was over 5% of the injected dose per gram tissue body weight, at 4 h post injection and above 4% in solid tumor. These data revealed localization of the tracer in the tumor tissues with high percentage sufficient to use ^99 mTc MTZL as promising tool for diagnosis of tumor.